Auriga Reiterates a 'Buy' on Medicis (MRX); Q1 Beat Underscores Execution - StreetInsider.com

Auriga reiterates a 'Buy' on Medicis (NYSE: MRX) price target of $47.00. Analyst, Louise Chen, said, "Despite generic competition for the legacy strengths of Solodyn and the company's switch to alternate fulfillment channels for unprofitable Rxs (35% of ...

Medicis Pharmaceutical profit drops sharply - AZCentral.com

The Scottsdale-based pharmaceutical company makes the acne drug Solodyn and wrinkle-busting treatments such as Restylane and Dysport. Medicis said revenue jumped to $201.7 million for the three months ended March 31, up from $164.9 million ...

Medicis Reports First Quarter 2012 Financial Results - msnbc.com

The Medicis Acne Products category includes primarily SOLODYN and ZIANA. Medicis recorded revenues of approximately $74.0 million associated with its non-acne products for the three months ended March 31, 2012, compared to revenues of ...

UPDATE: Jefferies Raises PT to $49 on Medicis; Visibility Post Q1 Upside - Benzinga

However, much of this comes out of Q2 as wholesalers work down inventory of Solodyn and Ziana. We are raising numbers and have much higher conviction in outyear earnings." MRX closed at $37.66 on Friday.

Medicis Outshines in 1Q - Analyst Blog - Boston Globe

The company benefitted from the alternate fulfillment initiatives and the corresponding reduction in customer rebates and higher sales of drugs Solodyn and Ziana. This segment primarily comprises Solodyn and Ziana. Non-acne product sales came in ...

Medicis Outshines in 1Q - Zacks.com

The company benefitted from the alternate fulfillment initiatives and the corresponding reduction in customer rebates and higher sales of drugs Solodyn and Ziana. This segment primarily comprises Solodyn and Ziana. Non-acne product sales came in at $74.0 ...

Jefferies Group Raises Price Target on Medicis Pharmaceutic (MRX) - zolmax.com

However, much of this comes out of Q2 as wholesalers work down inventory of Solodyn and Ziana. We are raising numbers and have much higher conviction in outyear earnings.” Medicis Pharmaceutic opened at 37.91 on Monday. Medicis Pharmaceutic has a 52-week ...

Jefferies Raises PT and Estimates on Magnachip Semiconductor (MX); Visibility Best In Years - StreetInsider.com

However, much of this comes out of Q2 as wholesalers work down inventory of Solodyn and Ziana. We are raising numbers and have much higher conviction in out-year earnings." FY12 EPS estimate raised from $2.67 to $2.77, FY13 from $3.14 to $3.27 and FY14 ...

Are You Ready To Buy What This Pro Investor Is Buying? - Seekingalpha.com

The company owes an important portion of its success to Solodyn, its extended-release minocycline drug for treating acne. Solodyn accounts for more than 50% of Medicis' revenue and perhaps an even larger portion of earnings, and is known as the largest ...